On Monday, Repare Therapeutics Inc (NASDAQ: RPTX) opened lower -3.10% from the last session, before settling in for the closing price of $1.29. Price fluctuations for RPTX have ranged from $1.23 to $8.49 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 1420.60% over the past five years. Company’s average yearly earnings per share was noted 3.89% at the time writing. With a float of $28.79 million, this company’s outstanding shares have now reached $42.51 million.
Let’s look at the performance matrix of the company that is accounted for 179 employees. In terms of profitability, gross margin is 97.75%, operating margin of -139.9%, and the pretax margin is -122.88%.
Repare Therapeutics Inc (RPTX) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Repare Therapeutics Inc is 32.27%, while institutional ownership is 45.01%. The most recent insider transaction that took place on Mar 28 ’24, was worth 12,243. In this transaction PRESIDENT AND CEO of this company sold 2,650 shares at a rate of $4.62, taking the stock ownership to the 110,049 shares. Before that another transaction happened on Apr 01 ’24, when Company’s PRESIDENT AND CEO sold 2,491 for $4.63, making the entire transaction worth $11,533. This insider now owns 107,558 shares in total.
Repare Therapeutics Inc (RPTX) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.71 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 3.89% per share during the next fiscal year.
Repare Therapeutics Inc (NASDAQ: RPTX) Trading Performance Indicators
Check out the current performance indicators for Repare Therapeutics Inc (RPTX). In the past quarter, the stock posted a quick ratio of 6.45. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.78.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.00, a number that is poised to hit -0.83 in the next quarter and is forecasted to reach -2.91 in one year’s time.
Technical Analysis of Repare Therapeutics Inc (RPTX)
Repare Therapeutics Inc (NASDAQ: RPTX) saw its 5-day average volume 0.46 million, a positive change from its year-to-date volume of 0.21 million. As of the previous 9 days, the stock’s Stochastic %D was 10.55%. Additionally, its Average True Range was 0.29.
During the past 100 days, Repare Therapeutics Inc’s (RPTX) raw stochastic average was set at 1.74%, which indicates a significant increase from 1.74% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 347.86% in the past 14 days, which was higher than the 150.49% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.9007, while its 200-day Moving Average is $3.3720. Nevertheless, the first resistance level for the watch stands at $1.2933 in the near term. At $1.3367, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.3833. If the price goes on to break the first support level at $1.2033, it is likely to go to the next support level at $1.1567. Assuming the price breaks the second support level, the third support level stands at $1.1133.
Repare Therapeutics Inc (NASDAQ: RPTX) Key Stats
There are currently 42,511K shares outstanding in the company with a market cap of 51.93 million. Presently, the company’s annual sales total 51,130 K according to its annual income of -93,800 K. Last quarter, the company’s sales amounted to 1,070 K and its income totaled -34,770 K.
